Nifedipine versus carvedilol in the treatment of de novo arterial hypertension after liver transplantation: Results of a controlled clinical trial

Authors

  • Alessandra Galioto,

    1. Department of Clinical and Experimental Medicine, University of Padova, Padova, Italy
    2. Department of Surgical and Gastroenterological Sciences, University of Padova, Padova, Italy
    3. Department of Environmental Medicine and Public Health, University of Padova, Padova, Italy
    Search for more papers by this author
  • Andrea Semplicini,

    1. Department of Clinical and Experimental Medicine, University of Padova, Padova, Italy
    2. Department of Surgical and Gastroenterological Sciences, University of Padova, Padova, Italy
    3. Department of Environmental Medicine and Public Health, University of Padova, Padova, Italy
    Search for more papers by this author
  • Giacomo Zanus,

    1. Department of Surgical and Gastroenterological Sciences, University of Padova, Padova, Italy
    Search for more papers by this author
  • Silvano Fasolato,

    1. Department of Clinical and Experimental Medicine, University of Padova, Padova, Italy
    2. Department of Surgical and Gastroenterological Sciences, University of Padova, Padova, Italy
    3. Department of Environmental Medicine and Public Health, University of Padova, Padova, Italy
    Search for more papers by this author
  • Antonietta Sticca,

    1. Department of Clinical and Experimental Medicine, University of Padova, Padova, Italy
    2. Department of Surgical and Gastroenterological Sciences, University of Padova, Padova, Italy
    3. Department of Environmental Medicine and Public Health, University of Padova, Padova, Italy
    Search for more papers by this author
  • Patrizia Boccagni,

    1. Department of Surgical and Gastroenterological Sciences, University of Padova, Padova, Italy
    Search for more papers by this author
  • Anna Chiara Frigo,

    1. Department of Environmental Medicine and Public Health, University of Padova, Padova, Italy
    Search for more papers by this author
  • Umberto Cillo,

    1. Department of Surgical and Gastroenterological Sciences, University of Padova, Padova, Italy
    Search for more papers by this author
  • Angelo Gatta,

    1. Department of Clinical and Experimental Medicine, University of Padova, Padova, Italy
    2. Department of Surgical and Gastroenterological Sciences, University of Padova, Padova, Italy
    3. Department of Environmental Medicine and Public Health, University of Padova, Padova, Italy
    Search for more papers by this author
  • Paolo Angeli

    Corresponding author
    1. Department of Clinical and Experimental Medicine, University of Padova, Padova, Italy
    2. Department of Surgical and Gastroenterological Sciences, University of Padova, Padova, Italy
    3. Department of Environmental Medicine and Public Health, University of Padova, Padova, Italy
    • Department of Clinical and Experimental Medicine, University of Padova, Via Giustiniani 2, Padova, Italy
    Search for more papers by this author
    • Telephone: 0039/0498212004; FAX: 0039/0498218676


Abstract

The aim of this study was to compare nifedipine and carvedilol in the treatment of de novo arterial hypertension after orthotopic liver transplantation (OLT). The study included 50 patients who developed arterial hypertension after OLT. Twenty-five patients received nifedipine (group A), and 25 received carvedilol (group B). Patients were defined as intolerant to nifedipine or carvedilol if severe adverse effects developed. These patients stopped the first drug and were switched to the other one. Patients were defined as full responders to monotherapy if there was normalization of blood pressure, and they were defined as partial responders by the need to add a second antihypertensive drug, ramipril. The 2 groups of patients were similar for baseline conditions. At the end of the study, patients intolerant to monotherapy were 48% of group A and 12.5% of group B (P < 0.01). Full responders were 20% of group A and 33.33% of group B (P < 0.01). Partial responders were 22% of group A and 54.1% of group B (P < 0.01). The addition of ramipril normalized blood pressure in 19% of partial responders to monotherapy (75% in partial responders to nifedipine and 30% in partial responders to carvedilol, P < 0.01). In responders to either monotherapy or combined therapy, there was a significant improvement of renal function. In responders to carvedilol, but not in responders to nifedipine, the daily dose of tacrolimus at 1 year should be reduced to 50% compared to the baseline dose to maintain the blood trough level in the therapeutic range. Liver Transpl 14:1020–1028, 2008. © 2008 AASLD.

Ancillary